News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Japan’s Astellas Pharma Inc. to Buy U.S. Agensys, Inc. for $387 Million
November 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Nov 27 (Reuters) - Japanese drugmaker Astellas Pharma Inc (4503.T: Quote, Profile, Research) said on Tuesday it would buy U.S. biotech company Agensys Inc for $387 million to boost its antibody research and development for cancer treatments.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Legal
Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal
November 6, 2025
·
2 min read
·
Tristan Manalac
Obesity
Novo’s Metsera Bid Attracts FTC Scrutiny as Pfizer Matches $10B Offer
November 6, 2025
·
3 min read
·
Tristan Manalac
Obesity
Is Metsera Worth the Fuss?
November 5, 2025
·
4 min read
·
Annalee Armstrong
Earnings
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
November 5, 2025
·
5 min read
·
Annalee Armstrong